Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References :
1. International Diabetes Federation IDF Diabetes Atlas, 9th edn. Brussels, Belgium . Atlas la Diabetes la FID (2019).at <http://www.idf.org/sites/default/files/Atlas-poster-2014_ES.pdf>
2. Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. lancet. Diabetes Endocrinol. 7 , 845–854 (2019).
3. Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol. 7 , 776–785 (2019).
4. Sorensen, C. M. & Holst, J. J. Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nat. Rev. Nephrol. 14 , 659–660 (2018).
5. León Jiménez, D., Cherney, D. Z. I., Bjornstad, P., Guerra, L. C. & Miramontes González, J. P. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am. J. Physiol. Renal Physiol. 315 , F1406–F1415 (2018).
6. Jiménez, D. L., Babkowski, M. C. & Miramontes González, J. P. GLP-1 and the renin–angiotensin–aldosterone system. Lancet Diabetes Endocrinol. 7 , 337 (2019).
7. Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394 , 121–130 (2019).
8. Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.Lancet Diabetes Endocrinol. 6 , 605–617 (2018).
9. Boye, K. S. et al. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.Clin. Ther. 40 , 1396–1407 (2018).
10. Moreno Obregón, F. et al. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.Diabetes Res. Clin. Pract. 158 , 107916 (2019).
11. Levey, A. S. et al. USing standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med.145 , 247–254 (2006).
12. Muskiet, M. H. A. et al. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol. 3 , 367–381 (2015).
13. Rossing, K. et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 66 , 1596–1605 (2004).